MétaCan
Menu
Back to cohort
Record W2068506100 · doi:10.1158/1535-7163.targ-11-a10

Abstract A10: Combined blockade of VEGF and Ang2 promotes dramatic tumor necrosis and growth inhibition of colorectal cancer xenografts.

2011· article· en· W2068506100 on OpenAlexaff
Alshad S. Lalani, Carla Castanaro, Alastair H. Kyle, Andrew I. Minchinton, Gavin Thurston, Christopher Daly

Bibliographic record

VenueMolecular Cancer Therapeutics · 2011
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicCancer, Hypoxia, and Metabolism
Canadian institutionsBC Cancer Agency
Fundersnot available
KeywordsAfliberceptAngiogenesisTumor hypoxiaColorectal cancerCancer researchMedicineHIF1APharmacologyOxaliplatinBevacizumabCombination therapyCancerBlockadeTumor progressionCD31Internal medicineChemotherapyReceptorRadiation therapy

Abstract

fetched live from OpenAlex

Abstract Background: VEGF and Angiopoietin-2 (Ang2) are secreted growth factors that are elevated in many human malignancies and function to regulate critical yet distinct aspects of tumor angiogenesis. While blockade of VEGF in combination with standard chemotherapy regimens has been demonstrated to improve survival in patients with metastatic colorectal cancer, the clinical benefit is transient, with most patients experiencing disease progression. We hypothesized that a combination treatment with agents that block the VEGF and Ang2 signaling pathways would provide more potent inhibition of tumor angiogenesis than single agent therapies, thereby resulting in more pronounced and/or durable effects on tumor growth. Methods: We assessed the antitumor effects of aflibercept (VEGF Trap) as a single agent or in combination with REGN910, a fully-human monoclonal antibody that specifically binds and potently inhibits Ang2 (each agent dosed at 15 mg/kg q4dx3). We employed whole tissue section mapping and multiplexed immunostaining techniques in Colo205 human tumor xenografts to assess changes in vessel density (CD31), hypoxia (pimonidazole) and tumor cell death (TUNEL). Results: The combination treatment of REGN910 plus aflibercept provided significantly greater tumor regression than single agent aflibercept treatment. No additive gross toxicities or body weight loss were observed following the combination treatment. Consistent with a more potent effect on tumor growth, the combination treatment caused a more pronounced decrease in tumor vessel density and a greater increase in tumor hypoxia at 24 hr post-treatment than either single agent. Finally, the combination treatment promoted much more dramatic tumor cell death at 72 hr than either single agent. Conclusions: Combined inhibition of VEGF and Ang2 using aflibercept plus REGN910 provides much more pronounced antitumor effects than either single agent, suggesting that combining these agents in the clinic is an attractive strategy to extend the benefit of anti-VEGF therapies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2011 Nov 12-16; San Francisco, CA. Philadelphia (PA): AACR; Mol Cancer Ther 2011;10(11 Suppl):Abstract nr A10.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.026
Threshold uncertainty score0.864

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.016
GPT teacher head0.244
Teacher spread0.228 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueMolecular Cancer TherapeuticsSame topicCancer, Hypoxia, and MetabolismFrench-language works237,207